Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A

As of June 30, 2026, Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 2.74B, placing it among publicly traded companies globally. Its enterprise value stands at 1.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A has 138.17M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 3.66, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A recorded 11.72M in income tax expense.

As of the close on October 23, 2026, Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 15.27% over the past 52 weeks. The 50-day moving average sits at 21.37, while the 200-day moving average is 23.51.

As of June 30, 2026, Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A holds 1.20B in cash and equivalents against 53.37M in total debt, resulting in a net debt position of -1.15B. Total book value stands at 1.74B, with working capital of 1.33B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.01 per share.

Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on July 22, 2026 with a 10:13 split ratio.